Eupraxia Pharmaceuticals Inc.
EPRX.TO
TSX
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 236.46% | -19.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 134.82% | -16.71% | |||
| Operating Income | -134.82% | 16.71% | |||
| Income Before Tax | -162.32% | 27.13% | |||
| Income Tax Expenses | 1,983.33% | -110.71% | |||
| Earnings from Continuing Operations | -162.53% | 27.19% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 26.25% | 17.65% | |||
| Net Income | -162.70% | 27.22% | |||
| EBIT | -134.82% | 16.71% | |||
| EBITDA | -135.54% | 16.88% | |||
| EPS Basic | -78.03% | 27.34% | |||
| Normalized Basic EPS | -89.03% | 29.16% | |||
| EPS Diluted | -78.03% | 27.34% | |||
| Normalized Diluted EPS | -89.03% | 29.16% | |||
| Average Basic Shares Outstanding | 38.96% | 2.75% | |||
| Average Diluted Shares Outstanding | 38.96% | 2.75% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||